

Genotyping of Escherichia Coli Isolated From Clinical and Hospitals Environment

Rana Abd ALameer *

Yahya A. Abbas **

Bassam Y. Khudaier ***

* Department Of Biology .College Of Science. University Of Thi-Qar

** AL-Nasiriyah Technical Institute

*** Department of Microbiology- College of Veterinary Medicine- University of Basraha

*E.mail: rana_alsalman@yahoo.com**Abstract**

Pathogenic *Escherichia coli* (*E. coli*) strains are known to cause intestinal and extraintestinal infections in human. A wide variety of infectious diseases could be caused by *E. coli* strains, including urinary tract infection, septicemia, newborn meningitis, central nervous system and respiratory system infections. Several bacterial agents can cause diarrheal and urinary tract infections, among these *E. coli* strains are detected as an important cause of morbidity and mortality of diarrhoea and UTI throughout the world. A total of 318 samples were collected during the period from September 2012 to march 2013. All specimens were screened for the presence of *E. coli* by cultured on MacConkey agar and Eosin-methylene blue agar then identified by biochemical tests and confirmed by API 20E system which revealed that: 90/318 (28.33%) gave positive growth for *E. coli* (15 (16.63%) environmental isolates and 75 (83.33%) clinical isolates) as following: 1/42 (2.38%) was obtained from burns, 7/25 (28%) from High vaginal swabs, 11/41 (26.82%) from Wounds infections, 18/33 (54.54%) from Diarrheal infections and 38/67 (56.71 %) from Urinary tract infections, while 15/110 (13.63%) from environmental isolates, The isolated were subjected to molecular identification as *E. coli* by used the intergenic spacer region primer (*ITS*). The confirmed isolates were examined to detect the phylogenetic group based on triplex PCR by using a combination of two genes (*chuA* and *yjaA*) and an anonymous DNA fragment. Universal primers (*ITS*) indicated that all isolates 90 (100%) gave positive results. The phylogenetic analysis revealed that 90 *E. coli* isolates belonged to three phylogenetic groups A & D 36 (40%) for each, while B 2 18 (20%) and no one isolates belong to B1 phylogenetic types. Out of the 16 of antibiotics used, 87 (92.22%) isolates were multidrug resistance. All isolates have been found resistant to at least one β -lactam Antibiotics.

Key words: *Escherichia coli*, Molecular identification, Genotyping

المستخلص

السلالات المرضية للاشريكية القولونية تسبب للإنسان اصابات داخل وخارج الامعاء. وهي مسؤولة عن طيف واسع من الامراض المعدية منها اصابات المجاري البولية، تسمم الدم، التهاب السحايا لحدوث الولادة وكذلك اصابات الجهاز العصبي المركزي و الجهاز التنفسي. من بين العديد من البكتريا المسببة لإصابات الاسهال والمجاري البولية تعد الاشريكية القولونية واحدة من اهم تلك المسببات جمعت حوالي 318 عينة خلال الفترة من ايلول 2012 ولغاية اذار 2013. أظهرت نتائج الزرع الأولي على وسط أكار الماكونكي واكار الايوسين مثيلين الازرق بعد التشخيص بالاعتماد على الصفات الزرعية والكيموحيوية وتوكيد التشخيص بأستعمال العدة API 20E. تبين ان 90 عينة من اصل 318 عينة اعطت نمو موجبا لبكتريا الاشريكية (15 عينة بيئية و 75 عينة سريرية) وكما يلي: 1/42 (2.38%) من الحروق، 7/25 (28%) من التهابات الاسهال و 11/41 (26.82%) من اصابات المجاري البولية في حين جمعت 15/110 (13.63%) من بيئات المستشفيات. ابدت جميع العينات (90) نتيجة موجه تجاه التشخيص الجزيئي بأستعمال البادئة (*ITS*). ثم فحصت بعد ذلك لكشف عن انماطها الجينية بأستخدام البودائ (*chuA, yjaA, TSP*). اذ توزعت العزلات الى ثلاث مجاميع جزيئية المجموعة A و D (40%)، B2 (20%)، بينما لم تنتمي أي من العينات الى المجموعة B1. أظهرت 87 (92.22%) عزلة مقاومة متعددة لمضادات الحيوية بعد استخدام 16 نوع من المضادات. كما و أظهرت جميع العزل مقاومه لنوع واحد على الاقل من مضادات البيتا لاكتام.

الكلمات المفتاحية: الاشريكية القولونية، التشخيص الجزيئي، التتميط الجيني.

Introduction

Escherichia coli was first identified by the German pediatrician Theodore Escherich in 1885 during his studies of the intestinal flora of infants, *E. coli* are common inhabitants of the small intestine and large intestine of mammal (Hooper & Gordon, 2001). They can occasionally be isolated in association with the intestinal tract of non-mammalian animals and insects. The presence of *E. coli* in the environment is usually considered to reflect fecal contamination and not the ability to replicate freely outside the intestine. There is evidence however to suggest that *E. coli* may freely replicate in tropical fresh water (Baylis *et al.*, 2006). *E. coli* is gram-negative, non-spore forming bacilli; they are approximately 0.5 μm diameter and 1.0-3.0 μm in length, within the periplasm is a single layer of peptidoglycan (Eisenstein, 1987). *E. coli* is usually motile in liquid by a set of peritrichous flagella, and also has fimbriae (pili) or fibrillar proteins often extending in great numbers from the bacterial surface and far out into the surrounding medium (Brenner *et al.*, 2004). One of the traits commonly encoded on the larger genetic islands of the different pathotypes of *E. coli* are additional pili (chaperone-usher and type IV pili families and non-pili adhesions) (Schreiber & Donnenberg, 2002). In some strains, the outer membrane of *E. coli* is covered by a polysaccharide capsule composed of K antigens. In other polysaccharides, the M antigens are synthesized under conditions of high osmolarity, low temperature, and low humidity (Schaechter, 2009). *E. coli* is a facultative anaerobe. It is capable of reducing nitrates to nitrites. When growing fermentatively on glucose or other carbohydrates, it produces acid and gas (mainly H_2 and CO_2). By traditional clinical laboratory biochemical tests, *E. coli* is positive for indol production and methyl red. Most strains are oxidase, citrate, urease, and hydrogen sulfide negative (Harley and Prescott, 1996). Most *E. coli* strains are capable of growing over a wide range of temperature approximately (15-48°C), the growth rate is maximal in the narrow range of (37°-42°C), it can grow within a pH range of approximately (5.5-8.0) with best growth occurring at neutrality. Some diarrheagenic *E. coli* strains have the ability to tolerate exposure to pH 2.0. Such an acid shock mimics transit through the stomach and induces expression of sets of genes involved in survival and pathogenesis (Braun and Braun, 2002). Clinically, two distinct types of pathogenic *E. coli* are recognized; One group commonly called

extraintestinal pathogenic *E. coli* (ExPEC) includes those *E. coli* associated with newborn meningitis (NBM) or sepsis and urinary tract infections (UTIs) (Johnson *et al.*, 2001). Several virulence factors (VFs) enhance the capacity of *E. coli* to cause systemic infections; unlike most commensal *E. coli* strains, extraintestinal isolates possess genes encoding putative VFs of extraintestinal pathogenic *E. coli* (ExPEC), which include various combinations of adhesins (P and S fimbriae), toxins (e.g., hemolysin and cytotoxic factor), polysaccharide coatings including (capsules and lipopolysaccharides), siderophores or iron acquisition systems (e.g., aerobactin and yersiniabactin), serum resistance mechanisms, and invasins. These VFs help the organisms to colonize host surfaces, avoid and/or subvert host defense mechanisms, injure and/or invade host cells and tissues, and incite a noxious inflammatory response, thereby leading to clinical disease (Bingen-Bidois *et al.*, 2002). The second group termed intestinal pathogenic *E. coli* (IPEC) includes *E. coli* responsible for a range of distinct classes of diarrhoeal disease. Six distinct groups have been defined within IPEC commonly associated with intestinal disease: enteroinvasive *E. coli* (EIEC), enterotoxigenic *E. coli* (ETEC), enteropathogenic *E. coli* (EPEC), enterohaemorrhagic *E. coli* (EHEC), enteroaggregative *E. coli* (EAEC) and the diffusely adherent *E. coli* (DAEC) (Donnenberg, 2002; Kaper *et al.*, 2004). *E. coli* serotypes defined by serum antibodies of the patient or animals that identify the specific type of antigen presented by bacteria. There are three major surface antigens that enable serotyping of *E. coli*. The "O" antigen, are somatic cell wall phospholipid-polysaccharide complex, the "H" antigens are components of flagella, and "K" antigens, are the surface or capsular antigens that are acidic polysaccharides (Doyle *et al.*, 1997). Over 700 antigenic types (serotypes) of *E. coli* are recognized. There are 173 known somatic (O), 80 capsular (K), and 56 flagellar (H) antigens, many of which can be subdivided into partial antigens (Rivera and Keen, 2001; Walter and Stamm, 2006). Evolutionary studies based on either DNA sequence analysis or multilocus enzyme electrophoresis has identified clonal phylogenetic groupings of *E. coli*. Phylogenetic studies have principally used the *E. coli* reference (ECOR) strain collection as a common reference for current evolutionary comparisons (Ochman & Selander, 1984). An alternative approach relying on the phylogenetic grouping of *E. coli* strains based on genetic markers, *chuA*, *yjaA*, and *TspE4.C2* DNA

fragment, was recently studied in application for microbial source tracking (MST). Based on the study by Clermont et al(2000) and recently ,Carlos et al (2010).E. coli can be categorized into four phylogenetic groups: A, B1, B2, or D, and then into subgroups: A0, A1, B1, B22, B23, D1, and D2. The groups were determined based on the presence or absence of *chuA*, *yjaA*, and DNA fragment TspE4.C2. *chuA* is known to be involved with heme transport while *yjaA* is involved in cellular response to hydrogen peroxide and acid stress, The function of TspE4.C2 is not yet discovered. E. coli containing combinations of one, two, all, or none of these genes were categorized into seven subgroups(Cherry,2011). Pathogenic E. coli strains derive mainly from phylogenetic group B2 and to a lesser extent group D (Ewers et al., 2007). Commensal E. coli by contrast are characteristically from phylogenetic groups A and B1(Lecointre et al., 1998; Johnson and Stell, 2000).The study was aimed to phylogeny of Escherichia coli isolated from clinical specimens (Burns,wounds , urinary tract infections , diarrhea , and vaginal swabs) and hospitals environments and determination their antimicrobial susceptibility.

Materials And Methods

Samples: samples were collected during the period from September 2012 to March 2013. A total of 318 samples (25 High vaginal swabs, 33 Diarrheal specimen, 41 Wounds swabs,42 Burns swabs,67 Urinary tract infections and 110 environmental) were collected from patients retened /or admitted to two (Al hussein Teaching Hospital and Bint Alhuda Teaching Hospital) hospitals and Public Health Laboratory in Thi-Qar province . All samples were collected by under sterile condition.

Isolation and Identification of Bacterial Isolates

All specimens were cultured on MacConkey agar and Eosin Methylene Blue agar plates ,They were incubated overnight at 37°C in bacteriological incubetors under aerobic conditions.Then typical lactose fermenter colonies on MacConky plates were picked off and transferred to new MacConkey agar plates for additionally overnight, Depending on morphological features of the colonies and microscopically examination with Gram's stain, The pure cultures were prepared for classical biochemical tests to differentiate *E.coli* from other *Enterobacteriaceae* depending on six biochemical tests (positive for methyl red and indole tests, negative for

the Voges-Proskauer, Simmon citrate, and urease tests), acid/acid with gas production in the Kliglers iron agar test(MacFaddin, 2000).The diagnosis of 90 E.coli isolates were confirmed by using API 20E system.

Antibiotic susceptibility

Testing susceptibility of 90 isolates against 16 antimicrobial agent (Bioanalyse, Turkey) from different classes has been determined using Kirby-Bauer disk diffusion method (Bauer *et al.*,1966).Inhibition zone around the antibiotic disk was measured according to CLSI(2007).

Polymerase Chain Reaction Assay

1- Preparing the Primers

The Alpha DNA primers were prepared depending on manufacturer instruction by dissolving the lyophilized product with sterile deionized water after spinning down briefly. Working primer tube was prepared by diluted with deionized D.W. The final picomoles depended on the procedure of each primer.

2 -E. coli DNA Extraction

This procedure was done by using commercially available Genomic DNA Mini kit (Blood/culture cell)(Geneaid , UKAS).The procedure was explained in details in user's manul.

3-PCR Supplies Assembling and Thermocycling Conditions

E. coli DNA templates were subjected to PCR using 4 sets (F and R) of primers to molecular identifies and determines *E.coli* phylogeny (Table 1). The PCR reaction mixture contained 20 µL of AccuPower® PCR PreMix each product line contains (1U *Top* DNA polymerase, 250µM dNTPas, 10 mM Tris-HCL(pH 9.0), 30 Mm KCl₂ ,1.5 Mm MgCl₂ , stabilizer and tracking dye),2µl of DNA tamplete, 1µl of each forward and reverse primers, then the volume completed to 20 µl by deionized D.W. All tubes then shacked well by vortex for 30 seconds. All materials were mixed in same PCR tube on ice bag under sterile condition. The PCR amplification conditions performed by using tow protocols depending on manufacturer's instruction(Table 2). The PCR amplification product was visualized by electrophoresis on 1.4% agarose gels for 45 min at 70 V. The size of the amplicons was determined by comparison to the 100 bp allelic ladder(Bioneer ,South korea).

Table (1): Intergenic spacer primers for ARISA analysis and *E. coli* ABD typing

| Primer Name | | DNA Sequences (5'-3') | Product Size bp | Reference |
|-------------|---|----------------------------|-----------------|----------------------------------|
| ITS | F | GTCGTAACAAGGTAGCCGTA | 28-1558 | (Cardinale <i>et al.</i> ,2004) |
| | R | GCCAAGGCATCCACC | | |
| chuA | F | CGGACGAACCAACGGTCAGGAT | 281 | (Kotlowski <i>et al.</i> , 2007) |
| | R | TGCCGCCAGTACCAAAGACACG | | |
| Yja | F | CGTGAAGTGCAGGAGACGCTGC | 226 | (Kotlowski <i>et al.</i> , 2007) |
| | R | TGCGTTCCTCAACCTGTGACAAACC | | |
| Tsp | F | GGGAGTAATGTCTGGGGCATTTCAG | 161 | (Kotlowski <i>et al.</i> , 2007) |
| | R | CATCGCGCCAACAAAGTATTACGCAG | | |

Table (2): Programs of PCR thermocycling condition

| Monoplex gene | Temperature (°C) / Time | | | | |
|---------------------------|---------------------------|-------------------------------|-----------|------------|-----------------|
| | Initial denaturation | Cycling condition (30 Cycles) | | | Final extension |
| | | denaturation | annealing | extension | |
| ITS | 94/3min | 94/45 sec | 55/1 min | 72/2min | 72/7 min |
| Multiplex gene | | | | | |
| ChuA Yja A TspE4.C2 | 94/ 4 min | 94/45 sec | 59/1min | 72/ 90 sec | 72/5min |

Results

1-Isolation and Identification of *Escherichia coli*

The number of *E. coli* isolated were 90 (28.33%),15 (16.63%) environmental isolates and 75(83.33%) clinical isolates. The environmental isolates of *E.coli* were collected as following : 3(20%) were isolated from each of washing basins and beds,2(13.33%)from each of operation hall, medical equipment and birth auditorium,1(6.66) from each of wards floor and tables (Table 3). While the clinical *E.coli* were isolated as following: 1(1.33%)was obtainedfromburns,7(9.33%)fromHighvaginalswabs,11 (26.82%)fromWounds infections,18(24.00%)from Diarrheal infections and 38 (56.71 %)from Urinary tract infections (Table 4). The identification of *E .coli* isolates was done in accordance to, morphological and biochemical tests. Their colony shape which appeared circular in shape, pink, non viscous colonies, lactose fermentation on MacConkey agar, and metallic sheen onEosin-methylene blue agar. The results of biochemical tests indicated positive for indole, Methyl red, gas production, A/A reaction, no H₂S production in TSI agar, while urease, Vogas-Proskuar and citrate were negative. Identification of *E.coli* were confirmed by using API 20E system. The results showed that all the 90 isolates were *E.coli*.

Table (3):Numbers and sources of environmental samples collected during the study

| Source | No. of samples | <i>E.coli</i> No. % |
|-------------------|----------------|---------------------|
| Operation hall | 11 | 2 (18.18) |
| medical equipment | 11 | 2 (18.18) |
| Birth auditorium | 11 | 2 (18.18) |
| Burns unit | 11 | - (0) |
| Wards | 11 | 1 (9.09) |
| Floor | 11 | 1 (9.09) |
| Beds | 11 | 3 (27.27) |
| Tables | 11 | 1 (9.09) |
| Walls | 11 | - (0) |
| Washing basins | 11 | 3 (27.27) |
| Total | 110 | 15 |

Table (4):The number and percentage of clinical samples were collected in the present study

| Sources of samples | No. of Samples | <i>E. coli</i> No. % |
|--------------------------|----------------|----------------------|
| Burns swabs | 42 | 1 (2.38) |
| Urinary tract infections | 67 | 38 (56.71) |
| Diarrheal specimen | 33 | 18 (54.54) |
| Wounds swabs | 41 | 11 (26.82) |
| High vaginal swabs | 25 | 7 (28) |
| Total | 208 | 75 (34.40) |

2-Antibiotic Susceptibility Pattern


The results showed out of 90 isolates, 83(92.22 %) were multidrug resistant which resistant to a minimum of three classes of the antibiotics tested.The hight percentage of resistant was for cephalothin (91.11%) followed by ampicillin(90.00%) then for piperacillin (85.55%).while the isolates showed low resistance for imipenem (3.33%)followed by amikacin (13.33%)then chloramphenicol (14.44%).(Table5)

Table5: Percentage of antibiotics resistance by *E.coli* against 16 types of antibiotics according to CLSI 2007 (n=90)

| Type of antibiotic | No.(%) of Resistant Isolates | | No. (%) of Intermediate Isolates | | No. (%) of Sensitive Isolates | |
|---------------------|------------------------------|---------|----------------------------------|---------|-------------------------------|---------|
| | No. | % | No. | % | No. | % |
| Amikacin (AK) | 12 | (13.33) | 45 | (50.00) | 33 | (36.00) |
| Ampicillin (AM) | 81 | (90.00) | 3 | (3.33) | 6 | (6.66) |
| Aztreonam (ATM) | 61 | (67.77) | 19 | (21.11) | 10 | (11.11) |
| Cefepime (FEP) | 43 | (47.77) | 16 | (17.77) | 31 | (34.44) |
| Cefotaxime (CTX) | 61 | (67.77) | 19 | (21.11) | 10 | (11.11) |
| Cefazidime (CAZ) | 65 | (72.22) | 19 | (21.11) | 6 | (6.66) |
| Ceftriaxone (CRO) | 63 | (70.00) | 15 | (16.66) | 12 | (13.33) |
| Cephalothin (KF) | 82 | (91.11) | 7 | (7.77) | 1 | (1.11) |
| Chloramphenicol(C) | 13 | (14.44) | 9 | (10.0) | 68 | (75.55) |
| Ciprofloxacin (CIP) | 23 | (25.55) | 37 | (41.11) | 30 | (33.33) |
| Gentamicin (CN) | 45 | (50.00) | 10 | (11.11) | 35 | (38.88) |
| Imipenem (IMP) | 3 | (3.33) | 1 | (1.11) | 86 | (95.55) |
| Nalidixic acid (NA) | 54 | (60.00) | 23 | (25.55) | 13 | (14.44) |
| Nitrofurantion (F) | 29 | (32.22) | 48 | (53.33) | 13 | (14.44) |
| Norfloxacin (NOR) | 22 | (24.44) | 16 | (17.77) | 52 | (57.77) |
| Piperacillin (PRL) | 77 | (85.55) | 3 | (3.33) | 10 | (11.11) |

3-Molecular identification of *E. coli* Isolates

This study was conducted to identify *E.coli* by using molecular method targeting ribosomal intergenic spacer analysis (RISA) involves the PCR amplification of the intergenic spacer region (*ITS*) located between the small (16S) and large (23S) subunits of the ribosomal gene. The DNA of all isolates was extracted and purified by using genomic DNA purification kit. The results were detected by electrophoresis on 1.4% agarose gel and exposed to U.V light in which the DNA appeared as compact bands. Universal primers amplified the intergenic spacer region between the 16S and 23S rDNA (*ITS*) indicated that all isolates 90(100%) gave positive results, Multiple interval bands within a lane reflect multiple *ITS* regions of different bacterial species. Figure(1)The *ITS* primer was the primary criterion for defining isolate as *E.coli* in this investigation



Figure(1): Ethidium bromide-stained agarose gel of PCR amplified products from extracted *E. coli* DNA amplified with primers *ITS*F and *ITS* R. Lane (L), DNA molecular size marker(100-bp ladder): Lanes (1-11) isolates show positive result with *ITS*Primer ,Lane (C), negative control

4- phylogenetic grouping of *E.coli* isolates

Phylogenetic analysis revealed that 90 *E.coli* isolates segregated in phylogenetic group A & D 36 (40.00%) for each, while B2 18 (20.00%) PCR assays of 75 clinical *E.coli* isolates showed that 30 isolates (40%) belonged to A& D for each and 15 isolates (20%) to B2 phylogenetic groups. PCR assays for phylotyping of 15 environmental isolates indicated that the strains distributed in three phylogenetic groups including 6 isolates (40%) in A&D and 3 isolates (20%) in B2 figure (2).




Figure (2): Ethidium bromide-stained agarose gel of PCR amplified products from extracted *E. coli* DNA amplified with primers *chuA*, *yjaA* and *TSPE4* .Lanes (L), DNA molecular size marker(100-bp ladder); Lanes (4,43,73) *E. coli* belong to group B2; Lanes (17,62,25), *E. coli* belong to group A ;Lanes(12,9,52);*E. coli* belong n to group D.

Discussion

The intestinal strains of *E. coli* that are not pathogenic, help in the synthesis of essential vitamins like Vitamin K and are essential for digestion. However some strains of *E. coli* are pathogenic and can cause significant morbidity and mortality in humans(Alessandro *et al.*,2006) The diseases caused by pathogenic strains of *E. coli* are classified into three main types. They are enteric or intestinal infections ,neonatal meningitis or neonatal sepsis and urinary tract infections. Physiological studies for *E. coli* have shown the ability of these organisms to adapt themselves to their characteristic habitats(Murthy,2006). *E.coli* accounts for approximately 70 to 95% of community-acquired cases and 50% of all hospital acquired infection(Kucheria *et al.*,2005). These organisms are responsible for significant social and economic costs for both communities and public health resources.

In the present study, The isolation percentage was correspond with many other studies that focused on predominant of *E.coli* among clinical and hospital environmental samples. In a local study by Al-Hilli(2010), 42(20%) *E.coli* isolates were obtained from 210 environment samples in Hilla ,Hadi(2008),found that *E.coli* was the most common (42.6%) organism isolated from patients with significant bacteriuria followed by *Klebsiella* spp .,AL-Amiedi(2007), noted the most isolate was *E.coli* (2.55%) isolated from every sterilized Hospital Environment of operation theater ,prematurity wards & emergency ward & kitchenat in Babylone Marternal &Children Hospital, Ali Shah et al.(2003),reported that of the 200 nosocomial Enterobacteriaceae isolates collected from different hospital wards, *E.coli* was the most frequent (35%). In another study, out of 387 Enterobacteriaceae isolates collected from six Singapore hospitals, 189(48.9%) were *E.coli*(Tan et al., 2009). In the United Arab Emirates, of the130 Enterobacteriaceae isolated from patients in six general hospitals, *E.coli* were predominant 83(63.8%) (Al- Zarouni et al., 2008).In the United States, Jarvis and Martone (1992) reported that *E. coli* as the most common nosocomial pathogen(13.7%)in surveillance at some hospitals, George et al.(2012) reported *E.coli* as among the most frequent(16.16%) isolates in hospitals in Kumasi, Ghana. In some hospitals, *E. coli* ranked first as the most common cause of hospital-acquired infections(Berkley et al.,2005).Also, *E.coli* strains were found to be the highest and most frequent among the pathogenic microorganisms isolated from ten teaching hospitals in China(Wang et al.,2010). Antimicrobial resistance in bacteria not only in hospitals but also in the community has become an important public health problem(Nugent et al.,2010).In response to these concerns, improving antibiotic prescribing, dose and duration of treatment and as well as monitoring antimicrobial resistance is part of the strategy to reduce antibiotic resistance(Fagon et al.,1994;Davy et al.,2005).The present study revealed that a high percentage of *E.coli* (92.22 %) were multidrug resistant showing resistance to a minimum of three classes of the antibiotics tested(Falagas and Karageorgopoulos, 2008). In Najaf, Al-Hilali(2010) revealed that a high percentage of *E.coli* isolates (90.9%) were multidrug resistant showing resistance to a minimum of three classes of the antibiotics tested, This percentage was higher in another study conducted by Al-Asady

(2009)found that all *E. coli* isolates (100%) were resistant to at least 12 antibiotics from a total of 26 antibiotics used in his study. Al-Hilli (2010)showed the same ratio (100%) of *E.coli* isolate obtained from Merjan Teaching Hospital in Hilla city too, were considered as multidrug resistant.High rates of resistance were recorded for Ampicillin (90.00%) and piperacillin(85.55%) Several reports have indicated that these drugs were also less effective against *E. coli* and other bacterial agents isolated in Najaf (Almohana,2004; Hadi, 2008; Al-Hilali 2010).The present study revealed that all the 90 *E.coli* isolates were resistant to at least oneofthese β -lactam antibiotics. Siegel(2008)reported that other risk factors may increase resistance to third generation cephalosporins including prolonged antibiotic exposure, severe chronic illness, prior infections, prolonged hospital stay, residence in a long-term care facility, and an indwelling catheter. Levels of resistance are (13.33%) and (50%) against amikacin and gentamicin, respectively.The percentages of aminoglycosides resistance described in present study agree with those reported by Kucukates and Kocazeybek (2002) in Turkey, who found that gentamicin and amikacin were relatively effective against *E. coli* isolates from various clinical samples. Arora and Devi (2007) found that the resistance to gentamicin and amikacin was detected in (28.89%) and (20.00%) of *E. coli* isolates ,Also there was a reduce activity of fluoroquinolones including ciprofloxacin and norfloxacin in *E.coli* isolates (25.55%and 24.44 resistant) comparable with the data from other studies in different parts of the world(El Metwally et al.,2007; carattoli et al., 2005; de Paula and Marin, 2008;Al-Hilali,2010) Who found that all of *E.coli* isolates were susceptible to these drugs.In agreement with Zamani et al.,(2012) this study demonstrated that (95.55%) *E.coli* isolates were susceptible to penems class of antibiotics (imipenem).While local studies by Hadi(2008),Al-Hilli (2010)and Al-Hilali(2010), who found that all *E.coli* isolates were susceptible to imipenems. The bacterial resistance to other non β -lactam antibiotics were also detected. All isolates showed (32.22%) resistance to nitrofurantoin and (14.44%) to Chloramphenicol. this results disagree with these obtained by Hadi(2008)who found that (52.6%) resistance to nitrofurantoin while(34.2%)resistance to chloramphenicol. Universal primers amplified the intergenic spacer region between the 16S and 23S rDNA genes, indicated that a total of 90(100%)isolates gave positive results with ITS primers that equal to target

product size (539 bp, 436 bp), all these 90 isolates were first confirmed as *E. coli* by biochemical tests with the API 20 E test. This finding goes in accordance with previous report by Hyatt et al.(2011) In study to identify unknown bacterial species were obtained from the American Type Culture Collection. Determination of *E. coli* phylogenetic type is being of great epidemiological importance because there are several reports indicating that there is a potential relationship between *E. coli* phylogenetic groups, age, sex and disease(Unno et al.,2009).Phylogenetic analyses have grouped *E. coli* into four main phylogenetic groups A, B1, B2 and D and there is a relation between the phylogeny and the virulence, the virulent extraintestinal strains belong mainly to B2 and to lesser extent to D group, whereas most commensal strains belong to groups A and B1(Desjardins et al., 1995).The reference techniques for phylogenetic grouping are multilocus enzyme electrophoresis and ribotyping. But, these methods are complex and time-consuming(Selander et al.,1986;Bingen et al., 1994;Desjardins et al.,1995).To overcome these drawbacks, Clermont et al.,(2000) described a simple and rapid technique for determination of the phylogenetic group of *E. coli* strains based on PCR detection of three specific phylogenetic group markers namely *chuA*, *yjaA*, and *TSPE4C2*. In this work PCR results of phylogenetic determination, showed that clinical Isolates mostly fell into group A and D(40 %),followed by B2(20%) while lack of the animal commensal B1 phylogenetic type. However, according to the results environmental isolates mostly belonged to A and D phylogenetic groups(40%)while group B2(20%)and no one isolates belong to B1 phylogenetic types. This result is in line with previous reports indicated that the dominance of A and D phylogenetic type among *E. coli* isolates in the clinical setting ,Alizade et al.(2013) who indicated that the most *E. coli* strains belonged to group A(42.2%) followed group D(33.33%) while group B2 (10.4%), Abd ul-Razzaq and Abd ul-Lateef (2011)in Hilla ,who observed that group A was most common isolates(44.4%) although some strains fall into group D(15.5%).while this finding contradicts the previously reported indicated that *E. coli* isolates belonging to phylogenetic group B2 have been shown to predominate in infants with neonatal bacterial meningitis , urinary tract and rectal isolates(Johnson et al.,2002; Zhang et al.,2002; Bashir et al., 2012) and reflects the increase in the

prevalence of the phylogenetic type D and phylogenetic type A among *E. coli* isolates on the expense of the phylogenetic type B2 in the clinical setting in Thi-Qar. It is not clear whether all *E. coli* in the intestinal tract of healthy individual at specific time should be considered commensal regardless of their phylogenetic background or only the isolates belonging to groups A and B1(Zhang et al., 2002).Similarly, it is not clear whether *E. coli* isolates belonging to groups A and B1 from patient with urinary tract infection should be considered as true pathogens or as commensal *E. coli* that produce infection in a compromised host(Sabate et al., 2006).Distribution of the phylogenetic type populations in *E. coli* in the clinical setting differ significantly from country to country, from city to another in the same country and most likely from a medical institution to another within the same city as well as from year to year in the same medical institution. Duriez et al.(2001)reported the possible influence of geographic conditions, dietary factors, use of antibiotics, and/or host genetic factors on the distribution of phylogenetic groups among commensal *E. coli* strains isolated from human stools from three geographically distinct populations in France, Croatia and Mali.

Reference

- Abdul-Razzaq, M.S. and Abdul-Lateef, L.A. (2011) . Molecular phylogeny of *Escherichia coli* isolated from clinical samples in Hilla, Iraq. *Afr J Biotechnol.*10(70): 15783-15787.
- AL-Amiedi,B.H (2007) Environmental Bacterial contamination of Babylon Marternal&children Hospital. *Medical Babylon* 2007 .4 (3) AND (4):5-6
- Al-Asady, F. M. H.(2009).Bacteriological study on ESBL- producing *Enterobacteriaceae* that cause bacteremia in children in Hilla city. M.Sc. Thesis. College of Medicine. University of Babylon.
- Alessandro Bartoloni; Lucia Pallecchi; Marta Benedetti; Connie Fernandez; Yolanda Vallejos; Elisa Guzman;Ana Liz Villagran; Antonio Mantella; Chiara Lucchetti; Filippo Bartalesi, Marianne Strohmeier, Angela Bechini,Herlan Gamboa, Hugo Rodriguez, Torkel Falkenberg; Goran Kronvall; Eduardo Gotuzzo; Franco Paradisi and Gian Maria Rossolini. (2006).Multidrugresistant Commensal *Escherichia coli* in Children, Peru and Bolivia. *Emerg Infect Dis.*12(6):911-912.

- Al-Hilali, S.A.M. (2010). Occurrence and molecular characterization of enteropathogenic *E.coli* serotypes isolated from children with diarrhoea in Najaf. M.Sc. Thesis. College of Medicine. Kufa University.
- Al-Hilli, Z. B.(2010). Dissemination of β -lactamases in *Escherichia coli* and *Klebsiella* spp. isolated from Merjan teaching hospital in Hilla City. M. Sc. Thesis Kufa University, College of Science.
- Ali Shah, A.; Hasan, F.; Ahmed, S. and Hameed, A. (2003). Prevalence of extended- spectrum β -lactamases in nosocomial and outpatients (ambulatory). *Pak J Med Sci.*, 19 (3): 187-191.
- Alizade, H.; Ghanbarpour, R. and Aflatoonian, M.R(2013) Virulence genotyping of *Escherichia coli* isolates from diarrheic and urinary tract infections in relation to phylogeny in southeast of Iran .*Tropical Biomedicine* .31(1): 174–182.
- Almohana, A. M. (2004). Prevalence and characterization of verotoxin producing *Escherichia coli* isolated from patients with diarrhea in Baghdad and Najaf. Ph.D. Thesis. Al-Mustansiriyah University.
- Al-Zarouni, M.; Senok, A.; Rashid, F.; Al-jasmi, S. M.; and Panigrahi, D. (2008). Prevalence and antimicrobial susceptibility pattern of extended-spectrum β -lactamases-producing Enterobacteriaceae in the United Arab Emirates. *Med Princ Pract.* 17: 32-36.
- Arora, U.; and Devi, P. (2007). Bacterial profile of blood stream infections and antibiotic resistance pattern of isolates. 9(4): 186-190.
- Bashir, S.; Haque, A.; Sarwar, Y.; Ali, A. and Anwar, M.I. (2012). Virulence profile of different phylogenetic groups of locally isolated community acquired uropathogenic *E. coli* from Faisalabad region of Pakistan. *Annals of Clin Microbiol Antimicrobials.* 11(23).
- Bauer, A. W., Kirby, W. M. M., Sherris, J. C. and Tenckhoff, M. (1966). An international multicenter cohort study. Intensive Care and AmpC β -lactamases and susceptibility to newer antimicrobial agents in complicated UTI. *Indian J Med Res.* 127: 85-88.
- Baylis, C.L.; Penn, C.W.; Thielman, N.M.; Guerrant, R.L.; Jenkins, C. and Gillespie, S.H. (2006). *Escherichia coli* and *Shigella* spp. In: Principles and Practice of Clinical Bacteriology. Gillespie, S.H and Hawkey, P.M. (2nd ed). England .28:347-348.
- Berkley, J.A.; Lowe, B.S.; Wang, I. M et al., (2005). Bacteremia among children admitted to a rural hospital in Kenya. *New Engl J Med* .352.(1): 39–47.
- Bingen, E. H.; Denamur, E. and Elion, J. (1994) Use of ribotyping in epidemiological surveillance of nosocomial outbreaks. *Clin Microbiol Rev.* 7: 311-327.
- Bingen-Bidois, M.; Clermont, O.; Bonacorsi, S.; Terki, M.; Brahimi, N.; Loukil, C.; et al. (2002) Phylogenetic analysis and prevalence of urosepsis strains of *Escherichia coli* bearing pathogenicity island-like domains. *Infect Immun;* 70: 3216-3226.
- Braun, V., Braun, M. (2002) Iron transport and signaling in *Escherichia coli*. *FEBS Letters.* 529 :78–85.
- Brenner D.J., Krieg, N. R. and Staley J. T. (2004). *Bergey's manual of systematic bacteriology.* (2nd ed). Volume two, The Proteobacteria. part B, The Gamma proteobacteria. Springer: 610.
- Carattoli, A. *et al.* (2005). Extended-spectrum β -lactamase in *Escherichia coli* isolated from dogs and cats in Rome, Italy, from 2001 to 2003. toxin-producing *Escherichia coli* in dogs with diarrhea. *Ciência Rural, Santa Maria,* 38:(6) 1682-1686.
- Cardinale, M., L. Brusetti, P. Quatrini, S. Borin, A. M. Puglia, A. Rizzi, E. Zanardini, C. Sorlini, C. Corselli and D. Daffonchio (2004). Comparison of different primer sets for use in automated ribosomal intergenic spacer analysis of complex bacterial communities. *Appl Environ Microbiol* 70(10): 6147-56.
- Carlos, C.; M.M. Pires; N.C. Stoppe; E.M. Hachich; M.I. Sato, T.A. Gomes; L.A. Amaral and L.M. Ottoboni. (2010). *Escherichia coli* phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. *BMC Microbiol.* 10:161-171
- Cherry Chu Yee Lee. (2011). Genotyping *Escherichia coli* Isolates from Duck, Goose, and Gull Fecal Samples with Phylogenetic Markers using Multiplex Polymerase Chain Reaction for Application in Microbial Source Tracking. *J Exp Microbiol and Immun (JEMI).* 15: 130 – 135.
- Clermont, O.; S. Bonacorsi and E. Bingen (2000). Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl Environ Microbiol* 66(10): 4555-8.
- Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). (2007). Performance standards for antimicrobial susceptibility testing, Seventeenth informational supplement. 27 (1).

- Davey P, Brown E, Fenelon L, *et al.*(2005) Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* .(4):CD003543
- De Paula, C. J. S. and Marin, J. M.(2008). Occurrence of non-O157 Shiga toxin-producing *Escherichia coli* in dogs with diarrhea. *Ciência Rural, Santa Maria*, 38:(6) 1682-1686.
- Desjardins, P.; Picard,B.;Kaltenbock, B.;Elion, J.and Denamur, E.(1995) Sex in *Escherichia coli* does not disrupt the clonal structure of the population: evidence from random amplified polymorphic DNA and restriction-fragment-length polymorphism. *J Mol Evol*. 41: 440-448.
- Donnenberg, M. S. (ed.) (2002) *Escherichia coli: Virulence Mechanisms of a Versatile Pathogen*. London: Academic Press.
- Doyle,M.P.;Zhoot, T.; Meng, J. and Zhao, S.(1997) *Escherichia coli* O157:H7.In.Microbiology-Fundamental and frontiers. American society of Microbiology Press. Washington DC.USA
- Duriez, P.; Clermont, O. ; Bonacorsi, S. ; Bingen, E. ; Chaventre, A.; Elion, J. ; Picard, B. and Denamur,E.(2001). Commensal *Escherichia coli* isolates are phylogenetically distributed among geographically distinct human populations.*Microbiology* 147:1671–1676.
- Eisenstein, B.I. Fimbriae. In: Roy, C.; Frederick, C.; *et al.* (Eds.) .(1987). *Escherichia coli* and *Salmonella Typhimurium*,(1st ed). ASM Press Washington, DC. 84–90
- El Metwally, H. A. R., Ibrahim, H. A. H., El-Atharn, M. N. and Arner, M. A. (2007). Multiplex PCR for detection of diarrheagenic *Escherichia coli* in Egyptian children. *J. Med. Sci.*, 7(2): 255-262.
- Ewers, C.; G. Li; H. Wilking; S. Kiessling; K. Alt ; E. M. Antao; C. Laturus; I. Diehl; S. Glodde; T. Homeier ; U. Bohnke; H. Steinruck; H. C. Philipp and L. H. Wieler (2007). Avian pathogenic, uropathogenic, and newborn meningitis-causing *Escherichia coli*: how closely related are they?. *Int J Med Microbiol*. 297(3): 163-76.
- Fagon JY, Novara A, Stephan F, *et al.*(1994) Mortality attributable to nosocomial infections in the ICU. *Infect Control Hosp Epidemiol*.15:428-34.
- Falagas, M.E. and Karageorgopoulos, D.E. (2008). Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. *Clin Infect Dis*.46: 2-1121.
- George,F.D; Gbedema,S.Y; Agyare,C.; Adu,F.; Boamah,V.E; Tawiah,A.A. and Sixtus Bieranye Bayaa Martin Saana(2012). Antibiotic Resistance Patterns of *Escherichia coli* Isolates from Hospitals in Kumasi, Ghana.
- Hadi, Z. J.(2008). Detection of extended-spectrum beta-lactamases of *Escherichia coli* and *Klebsiella* spp. isolated from patients with significant bacteriuria in Najaf. M. Sc. Thesis. College of Medicine. Kufa University.
- Harley, J. P. and L. M. Prescott (1996). *Laboratory Exercises in Microbiology*. (3rd Ed.). Mc Graw – Hill. Boston. 25: 91 – 92, 149 – 152, 183 – 185
- Hooper, I.V. ;Gordon, J.I. (2001). Commensal Host-Bacterial relationship in the gut. *Science*, 292:1115-1118.
- Hyatt,M;Swenson,G.J;Long,R,A.(2011).Molecular analysis of bacterial isolates used unknowns in bacteriology laboratory exercise.*Am Soc Microbiol*.81:375
- Jarvis, WR. and Martone, WJ. (1992). Predominant pathogens in hospital infections. *J Anti Chemo*.29: 19-24
- Johnson, J. R. and A. L. Stell (2000). Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise. *J Infect Dis*. 181(1): 261-72.
- Johnson, J. R.; Oswald, E. ; O'Bryan, T. T. ; Kuskowski, M. A. and Spanjaard, L. (2002). Phylogenetic distribution of virulence-associated genes among *Escherichia coli* isolates associated with neonatal bacterial meningitis in the Netherlands. *J Infect Dis*. 185:774–784.
- Johnson, J. R.; Stell, A. L.; Kaster, N.; Fasching, C. and T. T. O'Bryan (2001). Novel molecular variants of allele I of the *Escherichia coli* P-fimbrial adhesion gene papG. *Infect Immun*. 69: 2318 – 2327.
- Kaper, J. B., J. P. Nataro and H. L. Mobley (2004). Pathogenic *Escherichia coli*. *Nat Rev Microbiol*. 2(2): 123-40.
- Kotlowski, R., C. N. Bernstein, S. Sepehri and D. O. Krause (2007). High prevalence of *Escherichia coli* belonging to the B2+D phylogenetic group in inflammatory bowel disease. *Gut*. 56(5): 669-75.
- Kucheria R, Dasgupta P, Sacks SH, Khan MS and Sheerin NS(2005). Urinary tract infections: newinsights into a common problem. *Postgrad Med J*.81: 83-86.
- Kucukates, E. and Kocazeybek, B.(2002). High resistance rate against 15 different antibiotics in

- aerobic Gram-negative bacteria isolates of cardiology intensive care unit patients. *Ind J Med Microbiol.* 20 (4): 208-210.
- Lecointre, G.; L. Rachdi ; P. Darlu and E. Denamur (1998). *Escherichia coli* molecular phylogeny using the incongruence length difference test. *Mol Biol Evol.* 15(12): 1685-95.
- MacFaddin, J. F. (2000). *Biochemical Tests For Identification of Medical Bacteria*, 3rd Edition. Lippincott Williams and Williams.
- Murthy,K.(2006). Phenotypic characterization of *Escherichia coli* strains isolated from human intestinal & urinary tracts. M.Sc. Thesis. Institute of Applied Sciences. Wright State University.
- Nugent R, Back E, Beith A, editors.(2010). *The Race against Drug Resistance*. Washington, DC: Center for Global Development; 116.
- Ochman, H. and R. K. Selander (1984). Standard reference strains of *Escherichia coli* from natural populations. *J Bacteriol.* 157(2): 690-3.
- Rivera-Betancourt, M. and J. F. Keen (2001). Murine monoclonal antibodies against *Escherichia coli* O4 lipopolysaccharide and H5 flagellin. *J Clin Microbiol.*, 39: 3409 – 3434
- Sabate, M;Moreno, E;Perez, T; Andreu, A; Prats, G. (2006). Pathogenicity island markers in commensal and pathogenic *Escherichia coli* isolates. *Clin Microbiol Infect.* 12: 880-886.
- Schaechter M.(2009).*Encyclopedia of Microbiology*. Elsevier.125-132.
- Schreiber, W. ; Donnenberg, M.S.Type IV pili. In: Donnenberg, M.S. (Ed.).(2002). *Escherichia coli* Virulence Mechanisms of aVersatile Pathogen Academic Press New York, NY, .417.
- Selander, R. K.; Caugant, D. A.; Ochman, H.; Musser, J. M.; Gilmour, M. N.and Whittam, T. S. (1986) Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. *Appl Environ Microbiol.* 51: 873-884.
- Siegel, R. E. (2008). Emerging Gram-negative antibiotic resistance :daunting challenges, declining sensitivities, and dire consequences. *Respiratory Care .* 53(4).
- Tan, N.; Rao, P.; Arora, J.; and Dogra, A. (2008). Occurrence of ESBL and Amp-C β -lactamases and susceptibility to newer antimicrobial agents in complicated UTI. *Ind J Med Res.* 127: 85-88.
- Tan, T. Y.; Yong Ng, L. S.; He, J.;Koh, T. H. and Hsu, L. Y. (2009).Evaluation of screening methods to detect plasmid-mediated AmpC in *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* . *Antimicrob Agents Chemoth.* 53(1): 146-149.
- Unno,T; Han,D; Jang,J; Sun-Nim Lee; GwangPyo Ko; Ha YoungChoi; Joon Ha Kim; Michael J. Sadowsky and Hor-Gil Hur.(2009). Absence of *Escherichia coli* Phylogenetic Group B2 Strains in Humans and Domesticated Animals from Jeonnam Province,Republic of Korea._*Appl Environ Microbiol.*75(17) :5659–5666.
- Walter, E. and M. D. Stamm (2006). Host Pathogen interactions in community – aquired urinary tract infections *Trans. Am Clin Climatol Assoc.* 117: 75 – 84
- Wang, H.; Chen, M.; Y. Ni *et al.*,(2010) “Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003–2008, *Int J Antimicrob Ag.* 35(3): 227–234 .
- Zamani, Samin; Nasiri1, Mohammad Javad; Khoshgnab, Behshad Noorazar ;Ashrafi , Abbas and Abdollahi, Alireza .(2012) Evaluation of Antimicrobial Resistance Pattern of Nosocomial and CommunityBacterial Pathogens at a Teaching hospital in Tehran, Iran. *Acta Medica Iranica.*52(3):182-186.
- Zhang, L; Foxman, B. and Marrs C (2002). Both urinary and rectal *Escherichia coli* isolates are dominated by strains of phylogenetic group B2. *J Clin Microbiol*